Human DNA topoisomerase-IIα expression as a prognostic factor for transitional cell carcinoma of the urinary bladder

被引:19
作者
Koren, R [1 ]
Kugel, V
Dekel, Y
Weissman, Y
Livne, PM
Gal, R
机构
[1] Hasharon Hosp, Dept Pathol, Rabin Med Ctr, IL-49372 Petah Tiqwa, Israel
[2] Hasharon Hosp, Dept Urol, Rabin Med Ctr, IL-49372 Petah Tiqwa, Israel
[3] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
关键词
topoisomerase II-alpha; transitional cell carcinoma; urothelial tumour; survival; prognosis;
D O I
10.1046/j.1464-410X.2003.04118.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
To investigate the immunohistochemical expression of topoisomerase II-alpha (TII-alpha, a nuclear enzyme, the expression of which increases rapidly at the end of the S to G2/M phase and declines when mitosis ends) in bladder urothelial neoplasms (transitional cell carcinoma), and its correlation with grade, stage and survival. Histological sections from 57 urothelial neoplasms were stained immunohistochemically for TII-alpha expression; the percentage of positive cells in the area of greatest staining was recorded as the TII-alpha index. TII-alpha nuclear staining was positive in all the samples except one. The mean (sd) TII-alpha index was 10.7 (5.9) in urothelial neoplasms of low malignant potential (grade 1), 15.5 (5.0) in low-grade (grade 2) and 42.1 (13.4) in high-grade urothelial carcinoma (grade 3). The mean TII-alpha index was 10.7 (5.9), 26.3 (14.8) and 44 (19) in stages pTa, pT1 and pT2, respectively. The TII-alpha index was significant for predicting death from cancer, independently of the stage or grade of the disease (P = 0.019, hazard ratio 1.1). A higher TII-alpha index indicates a greater probability of recurrence of disease and lower overall survival. Therefore TII-alpha expression has prognostic value in bladder carcinoma.
引用
收藏
页码:489 / 492
页数:4
相关论文
共 23 条
[1]
Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide:: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop [J].
Arriola, EL ;
Lopez, AR ;
Chresta, CM .
ONCOGENE, 1999, 18 (04) :1081-1091
[2]
P-GLYCOPROTEIN, MULTIDRUG-RESISTANCE AND TUMOR PROGRESSION [J].
BRADLEY, G ;
LING, V .
CANCER AND METASTASIS REVIEWS, 1994, 13 (02) :223-233
[3]
DIFFERENT PATTERNS OF GENE-EXPRESSION OF TOPOISOMERASE-II ISOFORMS IN DIFFERENTIATED TISSUES DURING MURINE DEVELOPMENT [J].
CAPRANICO, G ;
TINELLI, S ;
AUSTIN, CA ;
FISHER, ML ;
ZUNINO, F .
BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1132 (01) :43-48
[4]
DAVIES SM, 1988, J BIOL CHEM, V263, P17724
[5]
BIOCHEMICAL AND PHARMACOLOGICAL PROPERTIES OF P170 AND P180 FORMS OF TOPOISOMERASE-II [J].
DRAKE, FH ;
HOFMANN, GA ;
BARTUS, HF ;
MATTERN, MR ;
CROOKE, ST ;
MIRABELLI, CK .
BIOCHEMISTRY, 1989, 28 (20) :8154-8160
[6]
The World Health Organization International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder [J].
Epstein, JI ;
Amin, MB ;
Reuter, VR ;
Mostofi, FK .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1998, 22 (12) :1435-1448
[7]
FRY AM, 1991, CANCER RES, V51, P6592
[8]
Guinee DG, 1996, CANCER, V78, P729
[9]
TOPOISOMERASE-II - A SPECIFIC MARKER FOR CELL-PROLIFERATION [J].
HECK, MMS ;
EARNSHAW, WC .
JOURNAL OF CELL BIOLOGY, 1986, 103 (06) :2569-2581
[10]
IMMUNOHISTOCHEMICAL STAINING FOR DNA TOPOISOMERASE-II IN NON-HODGKINS-LYMPHOMAS [J].
HOLDEN, JA ;
PERKINS, SL ;
SNOW, GW ;
KJELDSBERG, CR .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1995, 104 (01) :54-59